CrownBio Reveals Plans for Louisiana Research Facility
By
401 W. Admiral Doyle Drive, New Iberia, La.
New Iberia, La.—Crown Bioscience Inc. announced that the company will develop a pharmaceutical research and development facility at the New Iberia Research Center, located at 401 W. Admiral Doyle Drive, in New Iberia, La. The company will invest $1 million in the facility that will enable CrownBio to advance treatments for cardiovascular and metabolic disease research.
“We chose to expand in Louisiana, and specifically the NIRC, because of the growing biomedical science community there and the operational excellence that exists at NIRC. It was important for us to be located at a facility with multiple research capabilities that could harmonize well with the various efficacy and model development studies conducted by CrownBio,” said Jean-Pierre Wery, CEO of CrownBio, in prepared remarks. “We are confident Louisiana and NIRC, is the place for CrownBio to grow as we engage in the next leading phase of CVMD research that brings drugs to the clinical phase. We are very excited to contribute positively to the economic growth of the New Iberia region.”…
